Biologic Drug Substance Outsourcing

In Q4 2020, ISR asked 112 outsourcers of biologic API about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated to strategic partnerships (38%) followed by tactical outsourcing (33%). To learn more, follow the link to the Biologic API CMO Quality Benchmarking report preview.